COMP <GO>

CAPR vs RLMD // 10Y YIELD & FRED MACRO BETA

Capricor Therapeutics Inc. (NASDAQ) VS. Relmada Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CAPR 1 — RLMD 3

■ METRIC PARITY

LAST: $7.24 (+13.48%) • MKT CAP: $370.9M

macro-sensitivity

—

LAST: $3.84 (+7.26%) • MKT CAP: $381.9M

macro-sensitivity

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAPR VS. RLMD) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	CAPR	RLMD	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	-18.86%	-12.48%	-6.38	RLMD	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	3.38	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	1/9	+1.00	CAPR	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	42.3	52.7	-10.40	RLMD	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$370.9M	$381.9M	-$11.0M	RLMD	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	CAPR REV	RLMD REV	CAPR GROSS %	RLMD GROSS %	CAPR FCF	RLMD FCF
FY 2025	$302.8M	$165.5M	—	—	-$72.7M	-$45.8M
FY 2024	$22.3M	$234.9M	—	—	-$41.2M	-$51.8M
FY 2023	$25.2M	—	—	—	-$25.6M	—

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

CAPR // BETA —

RLMD // BETA —